These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 19010874)

  • 1. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab.
    Schultheis AM; Lurje G; Rhodes KE; Zhang W; Yang D; Garcia AA; Morgan R; Gandara D; Scudder S; Oza A; Hirte H; Fleming G; Roman L; Lenz HJ
    Clin Cancer Res; 2008 Nov; 14(22):7554-63. PubMed ID: 19010874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer.
    Loupakis F; Ruzzo A; Salvatore L; Cremolini C; Masi G; Frumento P; Schirripa M; Catalano V; Galluccio N; Canestrari E; Vincenzi B; Santini D; Bencardino K; Ricci V; Manzoni M; Danova M; Tonini G; Magnani M; Falcone A; Graziano F
    BMC Cancer; 2011 Jun; 11():247. PubMed ID: 21669012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer.
    Zhang W; Stoehlmacher J; Park DJ; Yang D; Borchard E; Gil J; Tsao-Wei DD; Yun J; Gordon M; Press OA; Rhodes K; Groshen S; Lenz HJ
    Clin Colorectal Cancer; 2005 Jul; 5(2):124-31. PubMed ID: 16098254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA repair gene associated with clinical outcome of epithelial ovarian cancer treated with platinum-based chemotherapy.
    Kang S; Sun HY; Zhou RM; Wang N; Hu P; Li Y
    Asian Pac J Cancer Prev; 2013; 14(2):941-6. PubMed ID: 23621265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer.
    Matulonis UA; Pereira L; Liu J; Lee H; Lee J; Whalen C; Campos S; Atkinson T; Hill M; Berlin S
    Gynecol Oncol; 2012 Jul; 126(1):41-6. PubMed ID: 22487536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
    Backes FJ; Richardson DL; McCann GA; Smith B; Salani R; Eisenhauer EL; Fowler JM; Copeland LJ; Cohn DE; O'Malley DM
    Int J Gynecol Cancer; 2013 Jun; 23(5):833-8. PubMed ID: 23640292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients.
    Etienne-Grimaldi MC; Formento P; Degeorges A; Pierga JY; Delva R; Pivot X; Dalenc F; Espié M; Veyret C; Formento JL; Francoual M; Piutti M; de Crémoux P; Milano G
    Br J Clin Pharmacol; 2011 Jun; 71(6):921-8. PubMed ID: 21204912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.
    Krivak TC; Darcy KM; Tian C; Armstrong D; Baysal BE; Gallion H; Ambrosone CB; DeLoia JA;
    J Clin Oncol; 2008 Jul; 26(21):3598-606. PubMed ID: 18640939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
    Garcia AA; Hirte H; Fleming G; Yang D; Tsao-Wei DD; Roman L; Groshen S; Swenson S; Markland F; Gandara D; Scudder S; Morgan R; Chen H; Lenz HJ; Oza AM
    J Clin Oncol; 2008 Jan; 26(1):76-82. PubMed ID: 18165643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
    Sánchez-Muñoz A; Mendiola C; Pérez-Ruiz E; Rodríguez-Sánchez CA; Jurado JM; Alonso-Carrión L; Ghanem I; de Velasco G; Quero-Blanco C; Alba E
    Oncology; 2010; 79(1-2):98-104. PubMed ID: 21079407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
    Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
    J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
    Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
    Robert NJ; Diéras V; Glaspy J; Brufsky AM; Bondarenko I; Lipatov ON; Perez EA; Yardley DA; Chan SY; Zhou X; Phan SC; O'Shaughnessy J
    J Clin Oncol; 2011 Apr; 29(10):1252-60. PubMed ID: 21383283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab.
    Zhang W; Gordon M; Press OA; Rhodes K; Vallböhmer D; Yang DY; Park D; Fazzone W; Schultheis A; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
    Pharmacogenet Genomics; 2006 Jul; 16(7):475-83. PubMed ID: 16788380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients.
    Di Salvatore M; Pietrantonio F; Orlandi A; Del Re M; Berenato R; Rossi E; Caporale M; Guarino D; Martinetti A; Basso M; Mennitto R; Santonocito C; Mennitto A; Schinzari G; Bossi I; Capoluongo E; Danesi R; de Braud F; Barone C
    Oncotarget; 2017 Mar; 8(10):16887-16898. PubMed ID: 28129643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab.
    Smerdel MP; Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
    Gynecol Oncol; 2010 Aug; 118(2):167-71. PubMed ID: 20471067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma.
    Stocker G; Ott K; Henningsen N; Becker K; Hapfelmeier A; Lordick F; Hois S; Plaschke S; Höfler H; Keller G
    Eur J Cancer; 2009 Dec; 45(18):3326-35. PubMed ID: 19822419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.
    Pander J; Gelderblom H; Antonini NF; Tol J; van Krieken JH; van der Straaten T; Punt CJ; Guchelaar HJ
    Eur J Cancer; 2010 Jul; 46(10):1829-34. PubMed ID: 20418097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
    Oza AM; Cook AD; Pfisterer J; Embleton A; Ledermann JA; Pujade-Lauraine E; Kristensen G; Carey MS; Beale P; Cervantes A; Park-Simon TW; Rustin G; Joly F; Mirza MR; Plante M; Quinn M; Poveda A; Jayson GC; Stark D; Swart AM; Farrelly L; Kaplan R; Parmar MK; Perren TJ;
    Lancet Oncol; 2015 Aug; 16(8):928-36. PubMed ID: 26115797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer.
    Jurado JM; Sánchez A; Pajares B; Pérez E; Alonso L; Alba E
    Clin Transl Oncol; 2008 Sep; 10(9):583-6. PubMed ID: 18796376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.